NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: DaCapo Brainscience Leadership Appointments and Company Focus
TL;DR
DaCapo Brainscience's new leadership positions the company to gain a competitive edge in developing first-in-class therapies for neurodegenerative diseases like Parkinson's.
DaCapo Brainscience uses a proprietary in vitro model that recapitulates human biology to systematically identify small molecule therapies targeting neurodegenerative disease pathways.
DaCapo Brainscience's strengthened leadership advances their mission to develop treatments that could slow or stop neurodegenerative diseases, improving quality of life for patients worldwide.
DaCapo Brainscience appointed biotech veteran Leslie Williams as CEO and promoted Warren Hirst to CSO while adding Mridul Mehta as CTO to accelerate drug discovery.
Found this article helpful?
Share it with your network and spread the knowledge!
DaCapo Brainscience announced the appointment of Leslie Williams as President and CEO, Mridul Mehta, PhD, as Chief Technology Officer, and the promotion of Warren Hirst, PhD, to Chief Scientific Officer.
These appointments strengthen DaCapo's leadership to advance its goal of identifying and developing small-molecule therapies to slow or stop neurodegenerative diseases, specifically helping transition the company from early discovery to a clinical-stage drug developer.
DaCapo Brainscience uses its proprietary discovery platform—an in vitro model of neurodegenerative disease that recapitulates human biology—to identify and develop small-molecule therapies aimed at slowing or halting disease progression, with an initial focus on Parkinson's disease.
Leslie Williams is a biotech veteran appointed as President and Chief Executive Officer to lead DaCapo Brainscience through its transition from early discovery to clinical-stage drug development.
Mridul Mehta, PhD, was appointed as Chief Technology Officer, and Warren Hirst, PhD, was promoted to Chief Scientific Officer.
The announcement was made on January 12, 2026, from Cambridge, MA.
You can view the full announcement, including downloadable images and bios, by clicking here.
Media and investors can contact DaCapo Brainscience via email at hello@dacapobrain.com.
The announcement is sourced from DaCapo Brainscience and distributed by Reportable, Inc., available at their respective websites.
Curated from Reportable
